ClinicalTrials.gg
RecruitingNCT07350629Updated Jan 20, 2026

Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment

An observational study in Aortic Regurgitation Disease, Aortic Stenosis Disease and Healthy Subjects, sponsored by Anhui Provincial Cancer Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Anhui Provincial Cancer Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
15
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Aortic Valve Insufficiency with a site in China — 17 open to participants now, 17 under way, none of them phase 3. Aortic Valve Insufficiency · China.

Planned enrollment
12th of 12
15 · median 3,750
Started
2025
with 5 others
Observational
12 of 23
9 open now
Primary completion
2026-02
later than 2 of 16 live
Registered
16th of 23
by date
Lead sponsor
1 of 23
Anhui Provincial Cancer Hospital

Among the 23 studies in Aortic Valve Insufficiency with a site in China, this one is the 12th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 2 of the 16 other live ones, and was the 16th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

17 of the 23 studies in Aortic Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Aortic Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether noninvasive real-time arterial waveform monitoring can be used to assess cardiovascular diseases in adults. The main question it aims to answer is:

Can photoacoustic imaging accurately capture arterial waveforms from patients' fingers? Can features extracted from the arterial waveforms reflect the type and severity of cardiovascular diseases? Participants will be asked to place their fingers into the imaging device, where their finger arterial pulse information will be noninvasively recorded.

03

Conditions studied

  • Aortic Regurgitation Disease
  • Aortic Stenosis Disease
  • Healthy Subjects
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from adult patients attending the cardiology department at the First Affiliated Hospital of University of Science and Technology of China, including individuals diagnosed with aortic regurgitation (AR) or aortic stenosis (AS), as well as healthy adult volunteers without known cardiovascular disease. Recruitment will focus on adults aged 18-80 years who are able to comply with finger arterial waveform measurement procedures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-80 years
  • Able to provide
  • For AR group: clinically diagnosed aortic regurgitation
  • For AS group: clinically diagnosed aortic stenosis
  • For healthy controls: no history of cardiovascular disease
  • Able to undergo finger arterial waveform measurement

Exclusion criteria

Exclusion Criteria:

  • History of recent cardiac surgery or intervention (\<6 months)
  • Hand disorders affecting finger mobility (e.g., arthritis)
  • Pregnant or breastfeeding women
  • Participation in other studies affecting arterial waveform
  • Unable to understand or comply with study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
15 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Healthy Subjects

    Healthy adult volunteers with no known cardiovascular disease will undergo noninvasive arterial waveform acquisition using the photoacoustic imaging device. No intervention is applied; data collection provides baseline waveform features for comparison with AR and AS patients.

  • Aortic Regurgitation (AR) Patients

    Participants diagnosed with aortic regurgitation (AR) will undergo noninvasive arterial waveform acquisition using a photoacoustic imaging device. No intervention is applied; data collection focuses on capturing finger arterial pulse waveforms to assess features associated with AR.

  • Aortic Stenosis (AS) Patients

    Participants diagnosed with aortic stenosis (AS) will undergo noninvasive arterial waveform acquisition using the same photoacoustic imaging device. No intervention is applied; data collection focuses on capturing finger arterial pulse waveforms to assess features associated with AS.

06

What researchers measure

Primary outcomes

  1. Evaluation of the state of aortic regurgitation and aortic stenosis by photoacoustic tomography

    To determine the feasibility of using photoacoustic tomography to differentiate aortic regurgitation and aortic stenosis based on arterial waveform measurements.

    Time frame: At enrollment (single time point)

Secondary outcomes

  1. Rise time of photoaocustic arterial waveform

    To determine the systolic upstroke rise time of arterial waveforms using photoacoustic tomography

    Time frame: At enrollment (single time point)

  2. Decay time of photoaocustic arterial waveform

    To determine the diastolic decay time of arterial waveforms using photoacoustic tomography

    Time frame: At enrollment (single time point)

  3. Dicrotic notch time of photoaocustic arterial waveform

    To determine the dicrotic notch time of arterial waveforms using photoacoustic tomography

    Time frame: At enrollment (single time point)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 20, 2026
StartActual
Dec 26, 2025
Primary completionEst.
Feb 2026
CompletionEst.
Feb 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07350629
Lead sponsor
Anhui Provincial Cancer Hospital
Responsible party
Wang Xiaojing (Chief Physician, Anhui Provincial Cancer Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Dec 26, 2025
Primary completion
Feb 2026 (estimated)
Completion
Feb 2026 (estimated)
Last update
Jan 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion